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Abstract
Perfluorooctanoate acid (PFOA) is a ubiquitous pollutant that causes liver toxicity in rodents, a 
process believed to be dependent on peroxisome proliferation activated receptor alpha (PPARα) 
activation. Differences between humans and rodents have made the human relevance of some 
health effects caused by PFOA controversial. We analyzed liver toxicity at 18 months following 
gestational PFOA exposure in CD-1 and 129/Sv strains of mice and compared PFOA-induced 
effects between strains and in wild type (WT) and PPARα-knockout (KO) 129/Sv mice. Pregnant 
mice were exposed daily to doses (0.01–5mg/kg/BW) of PFOA from gestation days 1–17. The 
female offspring were necropsied at 18 months and liver sections underwent a full pathology 
review. Hepatocellular adenomas formed in PFOA-exposed PPARα-KO 129/Sv and CD-1 mice, 
and were absent in untreated controls from those groups and WT 129/Sv. Hepatocellular 
hypertrophy was significantly increased by PFOA exposure in CD-1 and an increased severity was 
found in WT 129/Sv mice. PFOA significantly increased non-neoplastic liver lesions in PPARα-
KO mice (hepatocyte hypertrophy, bile duct hyperplasia and hematopoietic cell proliferation). 
Low dose gestational exposures to PFOA induced latent PPARα independent liver toxicity that 
was observed in aged mice. Evidence of liver toxicity in PPARα-KO mice warrants further 
investigation into PPARα independent pathways.
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Introduction
Perfluorooctanoate acid (PFOA) is an eight carbon perfluoroalkyl acid, a member of group 
of chemicals called perfluoroalkyl and polyfluoroalkyl substances (PFAS). It is produced 
both synthetically and through the degradation of other PFAS products. PFOA is commonly 
used as a water and oil repellent for fabric coatings, food storage containers, lubricants, and 
fire extinguishing foams. It is persistent in the environment and is bio-accumulative. The 
half-life in humans is estimated to be between 2.3 and 3.8 years (Lau 2012). Due to its 
environmental persistence, it is found ubiquitously in human serum (Kato et al. 2011). 
Children under the age of 11 have the highest concentrations of PFOA in their serum 
compared to teenagers, adults, and seniors (Kato et al. 2009; Schecter et al. 2012). PFOA 
transfers to the fetus, and is found in umbilical cord serum and breast milk, thus posing a 
risk for developmental exposure (von Ehrenstein et al. 2009, Ode et al. 2013(Fromme et al. 
2010)).
There are many differences in response to PFOA that are dependent on species. A recent 
review details species differences in elimination half-lives, with 
humans>>dogs=monkeys>mice>rabbits>rats and reported differences in sex-specific 
elimination rates for several PFAS (Lau 2012). Sex-specific differences in rat PFOA 
elimination half-lives are large; i.e., 2–4 hours in females and 4–6 days in males. Others 
species, including humans and mice, have closer to equal half-lives with regards to sex (Lau 
2012). To avoid daily episodic exposure situations due to a short PFOA elimination half-life 
in female rats, mice are the preferred laboratory model for developmental exposure studies. 
The half-life in mice is 17–19 days (Lau 2012). There are strain and/or developmental 
window differences in PFOA sensitivity observed in mice. Peripubertal PFOA exposure 
inhibited mammary gland growth in both Balb/c and C57Bl/6 wild type mice; however 
Balb/c mice were more sensitive to PFOA inhibition (Zhao et al. 2012). Furthermore, PFOA 
exposures that were one-fifth those needed in Balb/c and C57Bl/6 mice induced mammary 
epithelial delays in CD-1 mice following prenatal exposure (Macon et al. 2011).
Using all available published information, a mode of action (MOA) analysis of PFOA 
induced tumorigenicity and its related human relevance was performed recently (Klaunig et 
al. 2012). In the rodent analyses, the peroxisome proliferator activated receptor-alpha 
(PPARα) pathway was the proposed mode of carcinogenic action for PFOA in the rodent 
liver, based primarily on data from adult PFOA-exposed male rats or mice. While liver 
tumor induction is plausible in humans since the gene is expressed in the liver, the weight of 
evidence suggested that PPARα induction was not a primary MOA in humans. There is 
approximately 10-fold less mRNA for PPARα found in human liver compared to rodent 
livers (Palmer et al. 1998). Human PPARα mediates pathways controlling lipid metabolism 
and those pathways are reported to be independent of cell proliferation pathways in adult 
dosed male mice (Cheung et al. 2004). In COS-1 cells transfected with human or mouse 
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derived PPARα, PFOA activated the mouse PPARα to a greater extent than the human 
PPARα (Maloney and Waxman 1999, Takacs and Abbott 2007). This suggested that 
PPARα in human hepatocytes would be less responsive to PFOA than rodent hepatocytes. 
PFOA increased liver weight at 3 and 10 mg/kg in adult male cynomolgus monkeys, but 
microscopic effects were not evident (Butenhoff et al. 2002). PPARα may not be the MOA 
of PFOA induced liver toxicity in human liver but PPARα independent effects may exist in 
rodents/humans, thus it is important to evaluate the relevance of these findings to human 
health.
PPARα activation has been suggested to protect against chemically induced hepatobiliary 
injuries and this function could mask the potential toxicities of PFOA (Minata et al. 2010). 
In adult male 129/Sv mice (both wild type [WT] and PPARα-knockout [KO]) given PFOA 
daily for four weeks, PFOA induced a greater occurrence of cholestatic lesions in PPARα-
KO mice than in WT mice. Another weak PPARα ligand, Bezafibrate, induces cholestasis 
without neoplastic changes in PPARα-KO mice (Hays et al. 2005). In mice PFOA induced 
different hepatocyte injuries depending on the presence or absence of PPARα and 
expression of human or mouse PPARα. In a recent study, adult male 129/Sv WT, PPARα-
KO, and humanized PPARα (hPPARα) mice were treated with 1.0 or 5.0 mg/kg of PFOA 
for 6 weeks (Nakagawa et al. 2012). WT and hPPARα mice demonstrated hypertrophic 
hepatocytes and PPARα-KO mice presented with inflammatory cell infiltrations. There was 
also a difference in steatosis among the three groups. Microvesicular steatosis was seen in 
PPARα-KO and hPPARα mice, macrovesicular steatosis was only observed in the PPARα-
KO mice, and no changes were seen in WT mice. Mice expressing hPPARα produce 
PPARα at protein levels similar to WT mice, which are 10 times higher than what is found 
in human livers.
In this study we examine the long-term hepatic effects following developmental exposure to 
PFOA in mice with and without endogenous PPARα expression. Pregnant mice were dosed 
with PFOA or vehicle throughout the entire pregnancy and their offspring were assessed as 
adults for latent liver effects. We used two different strains of mice; 129/Sv (both WT and 
PPARα-KO mice) and CD-1. Our histopathological findings suggest that low dose 
gestational PFOA exposure can induce hepatic injury and cancer in a dose-dependent and 
PPARα independent manner. Further studies are warranted to evaluate PPARα independent 
mechanisms for liver toxicity following developmental PFOA exposures. Our initial 
mechanistic evaluations (Quist et al., this issue), confirm the findings here that suggest 
PFOA mediates its hepatotoxic effects on the liver via pathways other than PPARα.
Materials and methods
Animals
Timed-pregnant CD-1 mice (Charles River Laboratories, Raleigh, NC) arrived on 
gestational day (GD) 0 (sperm positive) at the US EPA where they were weighed upon 
arrival and distributed to make the average dam weight similar in each dose group. PPARα-
KO (null) mice (129S4/SvJae-Pparatm1Gonz/J, stock #003580) and 129/Sv WT mice 
(129S1/SvlmJ, stock #002448), were originally purchased from the Jackson Laboratory (Bar 
Harbor, ME), and were maintained as an inbred colony on the 129S1/SvlmJ background at 
Filgo et al. Page 3













the US EPA, Research Triangle Park, NC. Pregnant dams were housed individually in 
polypropylene cages and received chow (LabDiet 5001, PMI Nutrition International LLC, 
Brentwood, MO) and tap water ad libitum. AAALAC-accredited animal facilities were 
controlled for temperature (20–24 °C) and relative humidity (40–60%), and kept under a 12-
h light–dark cycle. Animals were treated humanely and with regard for alleviation of 
suffering and all animals protocols were approved by the US EPA National Health and 
Environmental Effects Research Laboratory Animal Care and Use Committee.
Dosing solution and procedures
PFOA, as its ammonium salt (>98% pure, linear product), was acquired from Fluka 
Chemical (Steinheim, Switzerland). PFOA dosing solution was prepared fresh daily in 
deionized water, and the dosing solution was administered at a volume of 10μl/g. Mice 
received either water vehicle or PFOA, as detailed below, by oral gavage once daily over the 
period of gestation. The highest dose (5mg PFOA/kg/day) was shown in a previous study 
using CD-1 mice (Lau et al., 2006) to induce hepatomegaly, with no effect on dam body 
weight gain and mild postnatal mortality (~25% increase in mortality from controls). The 
doses for the 129/Sv sub-strains were not identical due to reported differences in sensitivity 
to PFOA among these 2 substrains (Abbott et al. 2007)
Experimental design
Developmental exposure—Two blocks of CD-1 mice were used in these studies. The 
blocks were staggered by 4 weeks and some animals from these studies were used in other 
reports (Hines et al. 2009). The timed-pregnant animals were dosed with vehicle (distilled 
water), 0.01, 0.1, 0.3, 1, or 5mg PFOA/kg body weight (BW) resulting in a final number of 
29, 29, 37, 26, 31 and 21 female offspring surviving to 18 months of age (from 12, 12, 14, 
13, 12, and 6 pregnant dams), respectively, and included in this study. Some animals died 
before 18 months (28%, 17%, 16%, 28%, 24% and 22% of beginning n from control, 0.01, 
0.1, 0.3, 1, and 5mg PFOA/kg BW, respectively) due to sudden, unknown causes (found on 
AM check, 28% of early deaths), or severe dermatitis (common to CD-1; 32%) and other 
health problems (40%) that required preemptive euthanasia. The percentages of early death 
in our study are in line with reported survival rates in 8 studies of 78 week old CD-1 control 
mice, with an average death rate prior to 18 months of 21.7% (Table 2 in Giknis and 
Clifford, 2010). For the 129/Sv mice, three blocks of animals were used in these studies, 
each separated by 2–3 weeks. 129/Sv WT animals were dosed with vehicle, 0.1, 0.3, 0.6, or 
1mg PFOA/kg BW resulting in a final number of 10, 10, 8, 6 and 8 female offspring 
surviving to 18 months of age (to be consistent with the CD-1 animals) and included in the 
necropsy (from 7, 7, 5, 3 and 5 pregnant dams), respectively. PPARα-KO animals were 
dosed with vehicle, 0.1, 0.3, 1 or 3mg PFOA/kg BW resulting in a final number of 6, 10, 10, 
9 and 9 offspring (from 5, 9, 8, 7 and 9 pregnant dams), respectively. Details of survival in 
all groups are reported in Supplemental Data Table 1. Different dose ranges were used for 
the three strains due to differences in strain sensitivities to PFOA. The highest dose used per 
strain was selected to minimize developmental toxicities and litter loss (Abbott et al. 2007). 
The lower doses were selected that would result in adolescent mice with PFOA blood serum 
levels comparable to serum levels reported in highly exposed humans (Macon et al., 2011). 
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All animals received PFOA by oral gavage on the mornings of GD 1–17. Dams were 
weighed daily prior to dosing to determine dose amount.
At birth, pups were individually weighed and sexed. Consistent with previous PFOA 
research in CD-1 mice (Lau et al., 2006; White et al., 2007; Wolf et al., 2007), pups within a 
treatment group were pooled and randomly redistributed among the dams of their respective 
treatment groups, and litters were equalized to 10 pups (both sexes represented). Among the 
CD-1 mice, small litters (n < 4 pups) were excluded from the remainder of the study. All 
129/Sv pups were kept with their mothers to insure survival. Litter sizes are typically 
smaller in 129/SV mice than CD-1, and our litter size ranged from 4–8 pups. Pups were 
weaned at 21 days of age at which point only female offspring were retained for these 
studies and housed 3–5 mice per cage. Males were either used for breeding (controls) or 
were utilized in other studies. Growth data on these mice have been reported in Hines et al. 
(2009).
Data collection—The exposure schematic for these studies is shown in Figure 1. At 18 
months, liver and numerous other target organs (not described here), were collected from all 
surviving exposure groups. As denoted in Supplemental Data Table 1 and in Hines et al. 
(2009), some animals died prior to 18 months; these animals were not included here due to 
inconsistencies in age and quality of tissues that could be retrieved. This study was not 
designed as a liver carcinogenesis study (see Hines et al, 2009) and was the result of finding 
liver tumors in pre-terminal decedent PPARα KO animals where we expected to find none. 
Although liver tissues collected from animals sacrificed before 18 months indicated the need 
to focus attention on the liver in these studies, those data from animals <18 months of age 
were not included in this analysis, as those animals were sacrificed for various reasons, 
including severe dermatitis in some cases. To avoid bias in liver outcomes, only those mice 
living until 18 months were included in analyses.
Pathology Techniques—All 18 mo. old mice underwent a full necropsy. Livers were 
fixed in 10% neutral buffered formalin. 5μm sections were prepared from the left lobe of the 
liver and were stained with hematoxylin and eosin.
Sections underwent a pathology peer review by a team of board certified veterinary 
pathologists at the NIEHS (Pathology Working Group) for determination of and incidence 
of neoplastic and non-neoplastic lesions, and “INHAND” liver nomenclature was used in 
evaluating liver lesions (Thoolen et al., 2010). Neoplastic lesions were noted as presence of 
a lesion = +1, and absence = 0. Non-neoplastic lesions were graded on a severity scale of 1–
4 (1 = minimal, 2 = mild, 3 = moderate, 4 = severe).
Statistics—Data were analyzed using Cochran-Armitage trend tests for dose-related trends 
in incidences for each strain/condition combination. Fisher’s exact test was used to compare 
each dose group to the control group and to compare strains at the same condition. Kruskal-
Wallis analysis of variance (ANOVA) was used to test for differences in severities across all 
dose groups and Mann-Whitney tests was used to compare each dose group to the control 
group within the ANOVA, as the incidence data were not normally distributed. A p-value 
≤0.05 was considered statistically significant.
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Histopathological Findings in the Liver of CD-1 mice
Neoplastic and pre-neoplastic lesions were present in CD-1 mice treated with PFOA and a 
single malignant lymphoma was found in untreated animals (Table 1; top panel). Lymphoma 
was a background lesion in14.4% of 18 month old historical control CD-1females (Table 6 
in Giknis and Clifford, 2010). The overall incidence of malignant lymphoma in our study 
was 2.3% (4/173) or 3.4% in controls only (1/29). Hemangiosarcomas were observed in two 
animals in the high dose 5.0mg/kg BW PFOA group and one animal in the mid dose 
0.3mg/kg BW PFOA group, and hemangioma/hemangiosarcomas are found in only 0.4% of 
historical control female CD-1 mice (Giknis and Clifford, 2010). Hepatocellular adenomas 
occurred in every dose group except 1.0 mg/kg BW PFOA and were significantly increased 
compared to controls at 0.3mg/kg BW PFOA, with an overall incidence in treated animals of 
4.9% (7/144), and specific dose responses are shown in Table 1. This differs dramatically 
from historical control female CD-1 mice at 18 months of age, where this lesion has not 
been detected (Giknis and Clifford, 2010). Hepatocellular carcinomas occurred in mice 
dosed with 0.3 and 5.0mg/kg BW PFOA and histiocytic sarcomas developed in mice dosed 
with 0.1, 1.0, and 5.0mg/kg BW PFOA (both shown in Figure 2), but neither tumor type 
reached statistical significance (Table 1). Basophilic or eosinophilic foci were found in 3 
treated animals (0.01, 0.1, and 0.3mg/kg BW PFOA, respectively), and were also without 
statistical significance.
Numerous non-neoplastic liver lesions were noted in CD-1 mice. Developmental PFOA 
exposure caused a significant dose-related increase in oval cell hyperplasia (Table 1; bottom 
panel). There was also a dose-dependent increase in Ito cell and centrilobular hepatocyte 
hypertrophy following prenatal PFOA exposure. In several dosed groups, these incidences 
were 2 to 4-fold the incidence in the control group, and reached a significant increase above 
controls at 5.0mg/kg BW PFOA. Chronic inflammation was common in CD-1 mice, and 
there was a dose-related increase in severity scores in PFOA exposed livers; mean severity 
in the two highest dose groups was significantly higher than controls.
Histopathological Findings in the Liver of WT and PPARα-KO mice
In the vehicle treated 129/Sv WT mice, no tumors were found. A hemangiosarcoma 
developed in a PPARα-KO control mouse and was the only incidence of this tumor type in 
the 129/Sv strain (Table 2; top panel). The only tumor found in treated 129/Sv WT mice was 
a histiocytic sarcoma in the 0.1mg/kg PFOA dose group. Hepatocellular adenomas 
developed in five PFOA-treated PPARα-KO mice, with one affected animal in each dose 
group and in two animals in the highest dose group, leading to an overall incidence of 13.2% 
in treated animals (Table 2, Figure 3). However, this occurrence did not reach statistical 
significance (p=0.11). An Ito cell tumor developed in one PPARα-KO mouse treated with 
0.3mg/kg PFOA. Focal hepatocyte changes occurred in three PPARα-KO mice. Clear cell 
focus developed in one animal at 0.1mg/kg PFOA and eosinophilic foci developed in one 
animal at each of 0 and 0.3 mg/kg PFOA. In 129/Sv WT mice, eosinophilic foci developed 
in one animal at each of 0.3 and 0.6mg/kg PFOA. The lesion closest to reaching statistical 
significance was hepatocellular adenomas (p=0.11), and the 2–3 fold increase in incidence 
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over that seen in CD-1 likely failed to reach significance due to the smaller in this strain 
(difficult to breed and raise litters).
The non-neoplastic changes in the 129/Sv strain were also numerous. A significant PFOA 
dose-related increase was evident for incidences of both bile duct hyperplasia and bile duct 
inclusion bodies in PPARα-KO mice (Table 2; bottom panel). Conversely, the 129/Sv WT 
mice showed no increase in incidences of either bile duct hyperplasia (but a decreasing trend 
for severity with dose) or Hyaline droplet accumulation (but a decreasing trend for 
incidence) following PFOA exposures. Incidences of Ito cell hypertrophy decreased with 
PFOA treatment in PPARα-KO mice (Figure 4). Hematopoietic cell proliferation 
significantly increased with PFOA dose in PPARα-KO mice but was not significantly 
related to dose in the 129/Sv WT mice. The incidence of centrilobular hepatocyte 
hypertrophy significantly increased with PFOA dose in the PPAR KOs, and while the 
incidence in 129/Sv WT mice did not significantly change with dose, severity increased 
significantly with PFOA dose in 129/Sv WT mice. A similar increase in mean severity was 
noted in PPARα-KO mice, but that effect did not reach significance. These latter findings 
are novel and inconsistent with previous reports of adult PFOA exposure in male PPARα-
KO and WT mice that suggested minimal or absence of PFOA-induced hepatic microscopic 
abnormalities in animals null for mouse PPARα (Cheung et al., 2004; Nakamura et al., 
2009).
Discussion
In the present study, we describe several neoplastic and non-neoplastic signs of liver toxicity 
in two strains of 18 month old mice following prenatal PFOA exposures. These lesions 
demonstrate that low dose gestational PFOA exposure can impart long term and persistent 
liver injuries. Importantly, our previous data predict that 28 day old mice exposed to full 
gestational PFOA exposure at 0.3 mg PFOA/kg exhibited serum levels comparable to highly 
exposed humans (Emmett et al., 2006), and by 12 weeks of age the serum PFOA levels in 
those same mice had returned to background levels (Macon et al., 2011). There are still 
important differences between the mouse model and human exposure. The half-life of PFOA 
in the mouse is significantly shorter than that reported in humans. Therefore, mice require a 
higher in utero exposure to achieve similar serum concentrations as those reported in 
peripubertal children or adolescents in highly exposed regions of the U.S. (Emmett et al., 
2006). While human exposure to PFOA is reportedly higher in infants compared to their 
mother (8.0μg/L in serum of six month olds and 1.7μg/L in their mothers)(Fromme et al. 
2010), it is not as high as the concentrations just after birth in gestationally exposed mice. 
Humans are also continuously exposed to PFOA at low levels throughout life.
Centrilobular hepatocyte hypertrophy significantly increased in incidence with PFOA dose 
in CD-1 and 129/Sv PPARα-KO mice, and increased in severity in the 129/Sv WT mice. 
Hepatocellular adenomas were significantly increased in CD-1 mice, although a dose-
response relationship was not found. Hepatocellular adenomas were also evident in over 
13% of PFOA-exposed PPARα-KO mice, demonstrating that these lesions are stimulated by 
prenatal PFOA exposure, a process which is seemingly independent of PPARα activation. 
Importantly, hepatocellular adenomas are not found in historical CD-1 control female mice 
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(485 mice examined; Giknis and Clifford, 2010). Additionally, in the only other long-term 
study of the 129/Sv mice available, with similar power as this study (n=6–9/group), Peters 
and co-workers reported no hepatocellular adenomas in PPARα-KO and induction of those 
tumors in adult PPARα-WT mice fed Wyeth-14,643, a PPARα-inducer, after 11 months 
(Peters et al., 1997). These results indicate that Wyeth-14,643 induces hepatocellular 
adenomas via PPARα-activation and since Wyeth-14,643 wasn’t able to induce tumors in 
PPARα-KO animals and PFOA exposed PPARα-KO animals developed tumors in the 
present study, this may indicate that low level exposures to PFOA activates pathways other 
than PPARα in the mouse liver. Further, in the current study, bile duct hyperplasia and 
hematopoietic cell proliferation were two liver lesions that were only significantly increased 
with increasing dose of PFOA in the PPARα-KO mice. These long-term liver injuries in 
PPARα-KO mice suggest that potentially human relevant PPARα independent pathway(s) 
of hepatic injury and cancer exist following prenatal PFOA exposures.
Our findings here support the majority opinion of the US EPA Scientific Advisory Board 
(2006) during their review of EPA’s Draft Risk Assessment of Potential Human Health 
Effects Associated with PFOA and Its Salts, which concluded that “based on current 
evidence, that it is possible that PPARα agonism may not be the sole MOA for PFOA, that 
not all steps in the pathway of PPARα activation-induced liver tumors have been 
demonstrated, that other hepato-proliferative lesions require clarification, and that 
extrapolation of this MOA across the age range in humans is not supported.”
While there was not a significant increase in incidences of any one type of liver tumor in 
PPARα-KO mice, there was a higher incidence of tumors overall in the PFOA exposed 
PPARα-KO mice compared to the PFOA exposed 129/Sv WT mice, which may be due to 
some protective properties of PPARα (Ito et al. 2007). The 129/Sv WT mice had a single 
incidence of histiocytic sarcoma while the PPARα-KO mice had incidences of 
hemangiosarcoma (1 animal), hepatocellular adenoma (5 animals), and Ito cell tumor (1 
animal). The original design of these studies was not intended for tumor burden or liver 
toxicity evaluations, but livers were collected and evaluated at necropsy and became of 
interest when liver tumors were discovered in the PPARα-KO mice. Additional experiments 
using more animals are needed to validate our observations; that PPARα-KO mice are 
susceptible to PFOA induced liver injuries and tumor formation through PPARα 
independent and potentially human relevant pathways.
CD-1 mice and 129/Sv WT mice exposed to PFOA differed in that the CD-1 mice had 
increased incidences of hemangiosarcoma, Ito cell hypertrophy and oval cell hyperplasia 
and an increased severity of chronic active inflammation. The PPARα-KO mice had 
significantly increased incidences of bile duct hyperplasia and hematopoietic cell 
proliferation compared to the 129/Sv WT mice. Within the 129/Sv strain, PFOA results in 
an increase in bile duct hyperplasia and hematopoietic cell proliferation in the PPARα KO 
mice. Consistent in both the 129/Sv stains and CD-1 mice was that PFOA exposure 
increased centrilobular hepatocyte hypertrophy. Since all mice exposed to PFOA developed 
hepatocyte hypertrophy, regardless of the presence of PPARα, it is reasonable to conclude 
that a PPARα independent mechanism may be responsible for this change in hepatocytes. 
PFOA exposure resulted in hepatocellular adenoma in about 5% of CD-1 mice and those 
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tumors were also evident in nearly each dose group, as well as 13% of PFOA-exposed 
PPARα-KO mice. Perhaps in a larger animal study, hepatocellular adenoma may have 
reached significance in the PPARα-KO mice, as well.
PFOA has been linked to hepatic injury and the formation of the tumor triad of liver, Leydig 
cell and pancreatic acinar-cell tumors in adult-exposed male rats (Biegel et al., 2001). The 
mechanism for formation of those tumors is thought to be through PPARα dependent 
pathways, yet the direct mechanism is still incompletely characterized (Klaunig et al. 2012). 
Of the few studies that have evaluated low gestational exposure to PFOA (Lau et al. 2006, 
Wolf et al. 2007, Macon et al. 2011), this is the first to document persistent or long-term 
liver effects of this chemical in CD-1 or 129/Sv PPARα-KO mice. One study has reported 
that 3mg/kg BW gestational PFOA exposure in murine PPARα-KO, and human- or murine-
PPARα-expressing 129/Sv mice caused hepatocellular hypertrophy in only the murine 
PPARα-expressing mice at 20 days of age (Albrecht et al. 2013). The 129/Sv mouse strain 
used by those authors (obtained from the National Institutes of Health) is reportedly less 
sensitive to PFOA than 129/Sv WT mice in this study (obtained from the Jackson 
Laboratories), as their studies failed to recapitulate postnatal lethality at PFOA exposures of 
0.6 or 1.0mg/kg as was previously shown in these 129/Sv WT mice (Abbott et al., 2007), but 
caused a modest increase at 3 mg/kg (Albrecht et al. 2013). The authors further justified 
these differences in the background strain sensitivity by observing the maternal serum 
PFOA observed in mice treated with 3 mg PFOA/kg during gestation on PND20 in the 
Albrecht et al study (2013), which ranged from 2066 to 6812ng/ml, compared to the 
maternal serum PFOA observed in the Abbott et al. study (2007) mice at PND 22 that had 
been exposed to one-tenth that dose (0.3mg PFOA/kg) during gestation and generated a 
similar serum concentration (means at weaning: 2840 ng/ml, dams; 2150 ng/ml, pups). 
Another study using three strains of 8 week old adult male 129/Sv mice (WT, PPARα-KO 
and mice with humanized PPARα) orally gavaged with 1.0–5.0mg/kg BW PFOA for 6 
weeks reported liver injuries in all three strains, albeit they all looked different compared to 
each other (Nakagawa et al. 2012). These high dose effects are not surprising given that 
developmental PFOA exposures at 1 mg/kg in our previous studies had already been shown 
to induce transient hepatocellular hypertrophy in CD-1 mice (Macon et al. 2011).
Our findings suggest that 129/Sv PPARα-KO mice are susceptible to PFOA induced liver 
injury at relatively low exposures and these effects can be seen at 18 months in most dose 
groups, leading us to believe that the early lesions are permanent and potentially progress 
over time. The injuries to the bile ducts and hepatocytes in PFOA exposed mice may 
deteriorate further with age to manifest long after the chemical has been eliminated from the 
animals by PND 84 (Macon et al. 2011). This is further addressed in an accompanying paper 
in which PFOA-induced liver injury is manifested in CD-1 mice by PND21 (See Quist et al., 
this issue). PFOA liver injury in 129/Sv PPARα-KO mice (inflammatory cell infiltration, 
micro- and macrovesicular steatosis and hydropic degeneration) may be representative of 
disease pathways that are relevant to humans. While PPARα is present in human livers, it is 
detected at 1/10th the levels found in mice, and human PPARα does not appear to activate 
the cellular proliferation pathways as has been reported in mouse livers (Klaunig et al., 
2012). A humanized PPARα mouse model would still express PPARα at levels many times 
greater than that found in human liver. PFOA is easily excreted into the bile duct in WT 
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mice but is thought to accumulate in PPARα-KO mice; posing a potential risk for 
mitochondrial dysfunction (Nakagawa et al. 2012). This accumulation in PPARα-KO mice 
may also be a reason for the significantly increased bile duct hyperplasia and inclusion 
bodies noted in PFOA-exposed animals in this study, a finding inconsistent with that in the 
WT 129/Sv in these studies.
Other peroxisome proliferating chemicals have been shown to cause liver injury in PPARα-
KO mice. Male 129/Sv mice (PPARα-KO and WT of the NIH origin) were fed di (2-
ethylhexyl)phthalate (DEHP) in their diet from three weeks until 22 months. On the 23rd 
month they were assessed for liver toxicity. Surprisingly, and similar to what was found for 
PFOA in our study, the incidence of liver tumors was higher in PPARα-KO mice exposed to 
DEHP than in similarly exposed WT mice (Ito et al. 2007). One mode of action suggested 
by those authors was an increase in oxidative stress and the lack of the protective properties 
of PPARα, resulting in the PPARα-KO mice being more susceptible to tumor formation. 
We may have also seen this phenomenon in the PPARα-KO mice exposed to PFOA in this 
study. As previously stated, these PFOA-dosed PPARα-KO animals exhibited more tumors 
than their 129/Sv WT PFOA-dosed counterparts.
Another possible mechanism for PFOA-induced hepatic toxicity is mitochondrial disruption. 
One study (Berthiaume and Wallace 2002) used adult male Sprague-Dawley rats, treated 
with several peroxisome proliferators, including PFOA, at a very high dose (100mg/kg; 
orders of magnitude higher than body burdens in our studies) by single intraperitoneal 
injection to determine liver effects. On the third day after injection, livers were assessed for 
peroxisome proliferation and mitochondrial disruption. PFOA and perfluorooctanesulfonate 
(PFOS) were both shown to significantly increase peroxisomes compared to DMSO treated 
animals. However, only PFOA was shown to induce mitochondrial biogenesis. In their 
opinion, mitochondria disruption was not associated with the biological response to 
peroxisome proliferators.
Liver injuries in two strains of mice, significantly increased hepatocellular adenomas in 
CD-1 mice and potentially tumorigenesis in PPARα-KO mice, suggest that PFOA can cause 
liver toxicity through PPARα independent pathways following prenatal exposures that 
dissipate by about 12 weeks of age. Careful evaluation of the timing and doses of PFOA 
exposure, in addition to the background strain sensitivity, should be part of the health 
evaluation of PFOA going forward. Further evaluation of the health risks of PFOA is 
needed, to determine the human relevance of PFOA’s non-PPARα pathways which result in 
liver toxicity. Novel PFOA modes of action are suggested in the accompanying manuscript 
(Quist et al., this issue) which demonstrates that PFOA exposure is associated with hepatic 
mitochondrial alteration in CD1 mice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Exposure schematic for study of developmentally PFOA-exposed female mice. Exposure 
was during gestation and all tissues were collected from female offspring at 18 mo. of age.
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Histiocytic Sarcoma in PFOA-treated CD-1 mice. A–C) Liver, CD-1 mouse, 0.1 mg/kg 
PFOA. A densely cellular, poorly demarcated, infiltrative neoplasm was diffusely expanding 
centrilobular to midzonal areas, compressing and replacing the existing hepatic parenchyma. 
4X. HE. B) The neoplasm was composed of sheets of a homogeneous round cell population 
that is histiocytic in appearance and contains numerous multinucleated giant cells (arrows). 
20X. HE C) Higher magnification of multinucleated giant cells. 40X magnification. D–F) 
Liver, CD-1 mouse, 5.0 mg/kg PFOA. D) A similar population of histiocytic round cells 
were multifocally infiltrating the hepatic parenchyma, surrounding both central and portal 
veins. 4X. HE E) Neoplastic cells are often distending vascular structures and partially 
obstructing vascular lumina. 20X. HE F) Neoplastic round cells occasionally exhibit 
erythrophagocytosis. 40X. HE.
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Hepatocellular adenomas in PFOA-treated CD-1 and PPARα-KO mice. A–B) Liver, CD-1 
mouse, 0.3 mg/kg PFOA. A) Two, discrete, unencapsulated and expansile adenomas were 
arising from the subcapsular hepatic parenchyma (arrows). 2X. HE. B) Adenomas were 
composed of compact lobules of neoplastic hepatocytes exhibiting increased cytoplasmic 
basophilia with hyperchromatic nuclei. Hepatocytes are often distended with variable 
amounts of discrete, clear, intracytoplasmic vacuoles (lipid). 20X. HE. C–D) Liver, PPARα-
KO mouse, 3.0 mg/kg PFOA. C) A well-demarcated and unencapsulated, polypoid mass 
was arising from the capsular surface of the liver. 2X. HE. D) Hepatocytes were often 
enlarged and contained one or more enlarged hyperchromatic nuclei (karyomegaly). 20X. 
HE. Inset: Higher magnification of neoplastic hepatocytes. 40X. HE. E–F) Liver, PPARα-
KO mouse, 3.0 mg/kg PFOA. E) A similar, discrete, hepatic nodule (adenoma) was 
expanding the subcapsular region and compressing the underlying hepatic parenchyma. 2X. 
HE. F) Neoplastic cells exhibit increased basophilia and hyperchromatic nuclei with loss of 
the normal radial architecture and are sometimes bordered by large numbers of 
inflammatory cells. 20X. HE.
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Non-neoplastic hepatic lesions in PPARα-KO mice. A) Liver, PPARα-KO mouse, 0 mg/kg 
PFOA. Control liver from an untreated PPARα-KO mouse. PV = portal vein, arrow = bile 
duct. 40X. HE. B) Liver, PPARα-KO, 3.0 mg/kg PFOA. There is marked bile duct 
proliferation relative to the control mouse A (bile duct hyperplasia) as well as marked 
accumulations of homogenous, intracytoplasmic, brightly eosinophilic, globular material 
within biliary epithelial cells (hyaline droplet accumulation). Note the accumulation of 
primarily lymphocytic inflammatory infiltrates bordering the portal area, as well as 
increased deposition of fibrous connective tissue. PV = portal vein, arrow = bile duct. 20X. 
HE. Inset: Higher magnification of intracytoplasmic hyaline droplet accumulation within 
biliary epithelial cells and bile ducts. 40X. HE. C) Liver, PPARα-KO mouse, 0.3 mg/kg 
PFOA. Numerous hypertrophied Ito (satellite) cells contain a single, discrete vacuole that 
peripheralizes the nucleus (arrowheads). CV = central vein. 40X. HE. Insets: Enlarged 
images of hypertrophied Ito cells. D) Liver, PPARα-KO mouse, 3.0 mg/kg PFOA. 
Hepatocytes within the centrilobular and midzonal areas are slightly enlarged relative to the 
mice without hypertrophy in A and C. Hypertrophied hepatocytes are characterized by finely 
granular, eosinophilic cytoplasm with a “ground glass” appearance containing 
hyperchromatic and often enlarged (karyomegaly) nuclei (centrilobular to midzonal 
hepatocellular hypertrophy). Ito (satellite) cell hypertrophy and mixed fatty change are also 
present. CV = central vein. 40X. HE.
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